Fig. 2

Lower neutralizing antibody responses in allo-HCT patients than in healthy adults. a Correlation between anti-RBD Ab and 50% neutralizing Ab titers of SARS-CoV-2 wild type at day 49 in allo-HCT patients (n = 40). The red dots show the data from the 2 patients with prior SARS-CoV-2 infection while the blue dot shows the data of the patient with ongoing SARS-CoV-2 infection at the first vaccination. b 50% neutralizing Ab titers of SARS-CoV-2 wild type at day 49 in SARS-CoV-2 naive healthy adults (staff members of nursing homes, n = 40, black dots) versus SARS-CoV-2 naive allo-HCT patients (n = 37, orange dots) and SARS-CoV-2 naive allo-HCT patients without moderate/severe chronic GVHD and rituximab administration in the year before vaccination (n = 22, green dots). The horizontal solid lines show the median and the broken line shows the lower limit of quantification (LLOQ, 1/50). *P value < 0.05; **P value < 0.01; ***P value < 0.001; ****P value < 0.0001